SWOG0919: A Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia

British Journal of Haematology

Volumn 167, Issue 2, 2014, Pages 233-237

  Advani, Anjali S ^a   Mcdonough, Shannon ^b   Copelan, Edward ^c   Willman, Cheryl ^d   Mulford, Deborah A ^e   List, Alan F ^f   Sekeres, Mikkael A ^a   Othus, Megan ^b   Appelbaum, Frederick R ^g  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b SWOG STATISTICAL CENTER   (United States)

^c LEVINE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Acute myeloid leukaemia; Chemotherapy; Cholesterol; Pravastatin; Relapse

Indexed keywords

ANTHRACYCLINE; AZACITIDINE; CLADRIBINE; CLOFARABINE; CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; PRAVASTATIN; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANOREXIA; ARTICLE; BACTEREMIA; BLEEDING; BLEEDING TENDENCY; BLOODSTREAM INFECTION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONFUSION; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG INDICATION; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; ESOPHAGITIS; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL INFECTION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERGLYCEMIA; HYPERNATREMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; ILEUS; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LUNG INFECTION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RECURRENCE FREE SURVIVAL; SALVAGE THERAPY; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DRUG ADMINISTRATION; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTICENTER STUDY; RECURRENT DISEASE; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PRAVASTATIN; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908511175     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13035     Document Type: Article

References (20)

1. Banker, D.E., Mayer, S.J., Li, H.Y., Willman, C.L., Appelbaum, F.R. & Zager, R.A. (2004) Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukaemia cells. Blood, 104, 1816-1824.
2. Burnett, A.K., Russell, N.H., Kell, J., Dennis, M., Milligan, D., Paolini, S., Yin, J., Culligan, D., Johnston, P., Murphy, J., McMullin, M.F., Hunter, A., Das-Gupta, E., Clark, R., Carr, R. & Hills, R.K. (2010) European development of clofarabine as treatment for older patients with acute myeloid leukaemia considered unsuitable for intensive chemotherapy. Journal of Clinical Oncology, 28, 2389-2395.
3. Cheson, B.D., Bennett, J.M., Kopecky, K.J., Buchner, T., Willman, C., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo-Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Lowenberg, B., Sanz, D.R., Ohno, R. & Bloomfield, C.D. (2003) Revised recommendations of the Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukaemia. Journal of Clinical Oncology, 21, 4642-4649.
4. Estey, E.H., Kornblau, S., Pierce, S., Kantarjian, H., Beran, M. & Keating, H. (1996) A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukaemia. Blood, 88, 756.
5. Estey, E.H., Thall, P.F., Cortes, J.E., Giles, F.J., O'Brien, S., Pierce, S.A., Wang, X., Kantarjian, H.M. & Beran, M. (2001) Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukaemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood, 98, 3575-3583.
6. Ho, Y.K., Smith, R.G., Brown, M.S. & Goldstein, J.L. (1978) Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukaemia cells. Blood, 42, 1099-1114.
7. Kornblau, S.M., Banker, D.E., Stirewalt, D., Shen, D., Lemker, E., Verstovsek, S., Estrov, Z., Faderl, S., Cortes, J., Beran, M., Jackson, C.E., Chen, W., Estey, E. & Appelbaum, F.R. (2007) Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by addition of pravastatin to idarubicin and high dose Ara-C: a Phase 1 study. Blood, 109, 2999-3006.
8. Li, H.Y., Appelbaum, F.R., Willman, C.L., Zager, R.A. & Banker, D.E. (2003) Cholesterol-modulating agents kill acute myeloid leukaemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood, 101, 3628-3634.
9. Miller, K.B. & Daoust, P.R. (2000) Clinical manifestations of acute myeloid leukaemia. In: Hematology: Basic Principles and Practice (eds by Hoffman, R., Benz, E., Shattil, S., Furie, B., Cohen, H., Silberstein, L. & McGlave, P.), pp. 2017-2018. Churchill Livingston, Philadelphia, PA.
10. Newman, A., Clutterback, R.D. & Powles, R.L. (1994) Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin. Leukemia, 8, 2023-2029.
11. Rudling, M., Gafvels, M., Parini, P., Gahrton, G. & Angelin, B. (1998) Lipoprotein receptors in acute myelogenous leukaemia. American Journal of Pathology, 153, 1923-1935.
12. Slovak, M.L., Kopecky, K.J., Cassileth, P.A., Harrington, D.H., Theil, K.S., Mohamed, A., Paietta, E., Willman, C.L., Head, D.R., Rowe, J.M., Forman, S.J. & Appelbaum, F.R. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood, 96, 4075-4083.
13. Stirewalt, D.L., Appelbaum, F.R., Willman, C.L., Zager, R.A. & Banker, D.E. (2003) Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leukemia Research, 27, 133-145.
14. Thibault, A., Samid, D., Tompkins, A.C., Figg, W.D., Cooper, M.R., Hohl, R.J., Trepel, J., Liang, B., Patronas, N., Benzon, D.J., Reed, E. & Myers, C.E. (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clinical Cancer Research, 2, 483-491.
15. Thomas, X., Raffoux, E., Renneville, A., Pautas, C., de Botton, S., de Revel, T., Reman, O., Terre, C., Gardin, C., Chelghoum, Y., Boissel, N., Quesnel, B., Cordonnier, C., Bourhis, J.H., Elhamri, M., Fenaux, P., Preudhomme, C., Socie, G., Michallet, M., Castaigne, S. & Dombret, D. (2012) Outcome of treatment after first relapse in younger adults with acute myeloid leukaemia initially treated by the ALFA-9802 trial. Leukemia Research, 36, 1112-1118.
16. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellström-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.
17. Vignetti, M., Orsini, E., Petti, M.C., Moleti, M.L., Andrizzi, C., Pinto, R.M., Amadori, S. & Meloni, G. (1996) Probability of long-term disease-free survival for acute myeloid leukaemia patients after first relapse: a single-centre experience. Annals of Oncology, 7, 933-938.
18. Vitols, S., Gahrton, G., Ost, A. & Peterson, C. (1984) Elevated low density lipoprotein receptor activity in leukaemic cells with monocytic differentiation. Blood, 65, 1186-1193.
19. Vitols, S., Angelin, B., Ericsson, S., Gahrton, G., Juliusson, G., Masquelier, M., Paul, C., Peterson, C., Rudling, M. & Soderberg-Reid, K. (1990) Uptake of low density lipoproteins by human leukaemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 87, 2598-2602.
20. Williams, A.B., Li, L., Nguyen, B., Brown, P., Levis, M. & Small, D. (2012) Fluvastatin inhibits glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. Blood, 120, 3069-3079.